Thanks for your insight @sandybansal . I don’t think laurus synthesis div have capabilities for CAR-T cell therapy. It should be handled by ImmunoACT. Dr Chava might be referring to revenue generated by ImmunoACT, recognized for laurus at consolidated level – Similar to Laurus Bio.
Did some googling for CAR-T therapy and ImmunoACT to better understand the background.
Brief youtube video explaning CAR-T
CAR T-cell Therapy explained (Manufacturing process & how it works)
there are numerous hour long lecture/seminar discussing benefits, future potential/challenge for this technology.
ImmunoACT website itself is very good explaining background/Capabilities and Vision.
found following excerpt from money control interview ImmunoACT ceo, Rahul Parwar gave in Jun 2022.
“So we are hoping to complete the next phase of trials in about 12 to 18 months during which we can treat around 30 to 40 patients or even 50 patients. So, in about 18 months we can go for final approvals under the restricted use category while the large-scale trials can happen concurrently.”
| Subscribe To Our Free Newsletter |
